BioCentury
ARTICLE | Product Development

Pivotal meeting

How Cornerstone’s CPI-613 leapfrogged to pivotal trials in AML, pancreatic cancer

March 25, 2017 2:51 AM GMT
The compound has Orphan Drug designation in AML, pancreatic cancer and myelodysplastic syndrome (MDS).
Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Rafael Pharmaceuticals Inc.

BCIQ Target Profiles

Pyruvate dehydrogenase (PDH)